Clinical trial NCT00434356 (phase 2, status: terminated)
Conditions: metastatic breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: bevacizumab, sunitinib, paclitaxel
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Reason stopped: 
    based on data collected, the combination appeared to be poorly tolearated.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Signed Informed Consent Form

          -  Histologically or cytologically confirmed adenocarcinoma of the breast with measurable
             or non-measurable locally recurrent or metastatic disease

          -  Age ≥ 18 years

          -  Adequate left ventricular function at study entry, defined as an Left Ventricular
             Ejection Fraction (LVEF) > 50% by either Multi Gated Acquisition(MUGA) scan or
             Electrocardiogram (ECHO)

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  Ability and willingness to comply with study and follow-up procedures

        Exclusion Criteria:

          -  Unknown HER2 status or known HER2-positive status

          -  Prior chemotherapy for locally recurrent or metastatic disease

          -  Prior hormonal therapy within 2 weeks prior to Day 1

          -  Prior adjuvant or neoadjuvant taxane chemotherapy within 12 months prior to Day 1

          -  Prior adjuvant or neoadjuvant non-taxane chemotherapy within 6 months prior to Day 1

          -  For patients who have received recent radiotherapy, ongoing Grade ≥ 3 acute toxicity

          -  Patients with brain metastasis on full dose anticoagulation therapy

          -  Life expectancy of < 12 weeks

          -  Current, recent (within 4 weeks of Day 1), or planned participation in an experimental
             drug study

          -  Inadequate organ function within 28 days prior to Day 1

          -  Untreated abnormal thyroid function tests

          -  Uncontrolled serious medical or psychiatric illness

          -  Active infection requiring IV antibiotics at enrollment or randomization

          -  History of other malignancies within 5 years prior to Day 1 except for tumors with a
             negligible risk for metastasis or death, such as adequately controlled basal cell
             carcinoma or squamous-cell carcinoma of the skin or carcinoma in situ of the cervix

          -  Inadequately controlled hypertension

          -  Prior history of hypertensive crisis or hypertensive encephalopathy

          -  New York Heart Association (NYHA) Class II or greater CHF

          -  History of myocardial infarction or unstable angina within 12 months prior to Day 1

          -  History of stroke or transient ischemic attack within 12 months prior to Day 1

          -  Known central nervous system (CNS) disease except for treated brain metastasis

          -  Significant vascular disease (e.g., aortic aneurysm, aortic dissection) or recent
             peripheral arterial thrombosis within 6 months prior to Day 1

          -  History of hemoptysis within 1 month prior to Day 1

          -  Evidence of bleeding diathesis or significant coagulopathy (in the absence of
             therapeutic anticoagulation)

          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
             prior to Day 1 or anticipation of need for major surgical procedure during the course
             of the study

          -  Core biopsy or other minor surgical procedure, excluding placement of a vascular
             access device, within 7 days prior to Day 1

          -  History of abdominal fistula or gastrointestinal perforation within 6 months prior to
             Day 1

          -  Serious, non-healing wound, active ulcer, or untreated bone fracture

          -  Proteinuria at screening, as demonstrated by a urine protein/creatinine ratio of ≥ 1.0
             at screening

          -  Known hypersensitivity to any component of bevacizumab or sunitinib

          -  Pregnancy (positive pregnancy test) or lactation